Multiple Manufacturers

DOXIL

Manufacturer:

Multiple Manufacturers

Doxil HCPCS:

Q2050

HCPCS Code Descriptor:

Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg

Category:

Q Code

Doxil NDCs:

72603-0200-01, 16714-0856-01, 59676-0966-02, 68001-0345-26, 68001-0493-26, 70710-1531-01, 00338-0067-01, 00574-0931-25, 47335-0050-40, 43598-0683-25, 43598-0541-25, 72603-0103-01, 59676-0966-01, 16714-0742-01, 68001-0345-36, 68001-0492-36, 70710-1530-01, 00338-0063-01, 00574-0930-10, 47335-0049-40, 43598-0682-35, 43598-0283-35

Primary Type:

Oncology

Generic/Specialty Status:

Multi-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

59676-0966-02, 47335-0050-40, 43598-0683-25, 59676-0966-01, 47335-0049-40, 43598-0682-35

About Doxil:

DOXIL is an Oncology drug manufactured by Baxter Healthcare and administered via the Intravenous route of administration. The Q Code: Q2050 is aligned to the drug DOXIL.

ACCESS PRICING AND MORE BY REGISTERING

Q2050 Added Date:

July 1, 2013

Q2050 Effective Date:

July 1, 2013

Q2050 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Doxil billing and coding information.
Our team did not identify a source for Doxil patient assistance information. Please reach out to our team if you feel that this is a mistake.
DOXIL prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date.
Our team has not yet identified a source of side effects information for DOXIL. Please check back in a few weeks.